Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 36425.93 
• Atom Count: 2289 
• Residue Count: 319 
• Unique protein chains: 1

5EOB

Crystal structure of CMET in complex with novel inhibitor

• DOI: 10.2210/pdb5EOB/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)


• Deposited: 2015-11-10 Released: 2016-10-19 
• Deposition Author(s): Liu, Q., Chen, T., Xu, Y.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.75 Å
• R-Value Free: 0.197 
• R-Value Work: 0.173 

Literature

Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor

Zhan, Z., Peng, X., Liu, Q., Chen, F., Ji, Y., Yao, S., Xi, Y., Lin, Y., Chen, T., Xu, Y., Ai, J., Geng, M., Duan, W.

(2016) Eur.J.Med.Chem. 116: 239-251

• PubMed: 27061987 
• DOI: 10.1016/j.ejmech.2016.03.076


• PubMed Abstract: 
  

c-Met/HGF overexpression has been detected in many human malignancies including tumors which are resistant to anticancer therapy. Disrupting the aberrant c-Met/HGF axis has enjoyed significant progress in both preclinical and clinical antitumor campaign. To eliminate the OCH2-related metabolic deficiency of our previously reported triazolotriazine 2, we synthesized a series of CH2-/CF2-linked triazolotriazines and assessed their c-Met activities, leading to the highly potent compound 23 with IC50 values of 0.24 nM of enzymatic activity in c-Met and 0.85 nM of cellular activity in EBC-1 cancer cell line, as well as with complete tumor regression in EBC-1 xenograft mice model at dose of 25 mg/kg via oral administration. Based on its potent anti-proliferative activities and favorable pharmacokinetic properties, 23 has been selected as a drug candidate for preclinical investigation.

---

Related Citations: 

• Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors
  Wu, K.,Ai, J.,Liu, Q.,Chen, T.,Zhao, A.,Peng, X.,Wang, Y.,Ji, Y.,Yao, Q.,Xu, Y.,Geng, M.,Zhang, A.
  (2012) Bioorg.Med.Chem.Lett. 22: 6368




---

Organizational Affiliation: 

Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai 201203, China.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Hepatocyte growth factor receptor	A	319	Homo sapiens	Mutation(s): 0  Gene Names: MET EC: 2.7.10.1
Find proteins for P08581 (Homo sapiens) Go to Gene View: MET Go to UniProtKB:  P08581

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
5QQ	A	6-[bis(fluoranyl)-[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]methyl]quinoline C20 H11 F3 N6 XQEJWZGYFBXKIF-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
5QQ	IC50: 0.24 nM BINDINGMOAD

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.75 Å
• R-Value Free: 0.197 
• R-Value Work: 0.173 
• Space Group: P 1 2₁ 1

Unit Cell:

Length (Å)	Angle (°)
a = 37.880	α = 90.00
b = 43.390	β = 92.68
c = 86.080	γ = 90.00

Software Package:

Software Name	Purpose
PHASER	phasing
PDB_EXTRACT	data extraction
XSCALE	data scaling
PHENIX	refinement
XDS	data reduction
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2015-11-10 
• Released Date: 2016-10-19 
• Deposition Author(s): Liu, Q., Chen, T., Xu, Y.

Revision History 

• Version 1.0: 2016-10-19
  Type: Initial release